Detalles de la búsqueda
1.
ABBV-319: A CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
Blood
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38701407
2.
Multicentered masked placebo-controlled phase 2 clinical study of an extended duration transdermal buprenorphine solution for postoperative pain in cats.
J Vet Pharmacol Ther
; 45 Suppl 1: S40-S51, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35790010
3.
Multicentered masked placebo-controlled phase 3 clinical study of an extended duration transdermal buprenorphine solution for post-operative pain in cats.
J Vet Pharmacol Ther
; 45 Suppl 1: S52-S66, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35790011
4.
Single-dose pharmacokinetics and bioavailability of a novel extended duration transdermal buprenorphine solution in cats.
J Vet Pharmacol Ther
; 45 Suppl 1: S31-S39, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35790014
5.
Margin of safety of extended-duration transdermal buprenorphine solution following multiple-dose administrations to cats.
J Vet Pharmacol Ther
; 45 Suppl 1: S67-S84, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35790012
6.
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1630-1642, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33129376
7.
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Blood
; 130(22): 2392-2400, 2017 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28847998
8.
Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials.
Hematol Oncol
; 2018 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29672885
9.
Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.
Hematol Oncol
; 36(1): 37-43, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28707346
10.
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Eur J Clin Pharmacol
; 74(4): 413-421, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29302721
11.
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Hematol Oncol
; 35(4): 679-684, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27982454
12.
Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and disease.
Transfusion
; 52(5): 963-73, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22229348
13.
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
J Clin Oncol
; 40(31): 3576-3586, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36029527
14.
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Clin Pharmacol Ther
; 109(2): 424-432, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32749675
15.
Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.
J Pharmacol Exp Ther
; 332(1): 229-37, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19808699
16.
Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotin.
Transfusion
; 50(12): 2553-64, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20561297
17.
Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin.
Clin Transl Sci
; 13(3): 555-562, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31961475
18.
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Leuk Lymphoma
; 61(1): 56-65, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31549889
19.
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure-Response Analyses Underutilized?
CPT Pharmacometrics Syst Pharmacol
; 8(3): 138-145, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30659774
20.
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Clin Cancer Res
; 25(21): 6309-6319, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31420359